TP53 co-mutation with EGFR has conferred worse overall survival to first line EGFR TKI use in real world settings and our gender disparity findings in HR+ NSCLC suggest that further investigation is needed (43). The gene discussed is TP53; the disease is non-small cell lung carcinoma.